| Autor: |
Wu, Yi-Long, Cheng, Ying, Zhou, Jianying, Lu, Shun, Zhang, Yiping, Zhao, Jun, Kim, Dong-Wan, Soo, Ross Andrew, Kim, Sang-We, Pan, Hongming, Chen, Yuh-Min, Chian, Chih-Feng, Liu, Xiaoqing, Tan, Daniel Shao Weng, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Park, Keunchil, Yang, James Chih-Hsin, Wu, Yi-Long, Liu, Xiaoqing, Liu, Zhe, Lu, Shun, Chen, Xi, Pan, Hongming, Wang, Mengzhao, Yu, Shiying, Zhang, Helong, Zhang, Yiping, Fang, Jian, Li, Wei, Zhou, Jianying, Zhao, Jun, Cheng, Ying, Yang, Chih-Hsin, Chang, Gee-Chen, Chen, Yuh-Min, Hsia, Te-Chun, Chian, Chih-Feng, Yang, Cheng-Ta, Wang, Chin-Chou, Kim, Sang-We, Park, Keunchil, Kim, Dong-Wan, Cho, Byoung Chul, Lee, Ki Hyeong, Kim, Young-Chul, An, Ho Jung, Woo, In Sook, Cho, Jae Yong, Shin, Sang Won, Lee, Jong-Seok, Kim, Joo-Hang, Yoo, Seung Soo, Kato, Terufumi, Shinagawa, Naofumi, Soo, Ross Andrew, Tan, Shao Weng Daniel, Ngo, Lynette Si-Mien, Ratnavelu, Kananathan, Ahmad, Azura Rozila, Liam, Chong Kin, de Marinis, Filippo, Tassone, Pierfrancesco, Molla, Amelia Insa, Calles Blanco, Antonio, Lazaro Quintela, Martin Emilio, Felip Font, Enriqueta, Dingemans, Anne-Marie, Bui, Lynne |
| Zdroj: |
The Lancet Respiratory Medicine; November 2020, Vol. 8 Issue: 11 p1132-1143, 12p |
| Abstrakt: |
We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or METamplification having acquired resistance to EGFR inhibition. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
